Different response patterns in hallucinations and delusions to antipsychotic treatment

References

• Tandon R. Antipsychotics in the treatment of schizophrenia: an overview. J Clin Psychiatry. 2011;72:4–8.
   PubMed Web of Science ®Google Scholar
• Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, “just the facts” 4. Clinical features and conceptualization. Schizophr Res. 2009;110:1–23.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association 2013. Diagnostic and statistical manual of mental disorders: DSM-5. Arlington (VA): American Psychiatric Association.
   Google Scholar
• WHO. 1993. International statistical classification of diseases and related health problems – 10th revision.
   Google Scholar
• Haddad PM, Correll CU. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol. 2018;8:303–318.
   PubMed Web of Science ®Google Scholar
• Harvey RC, James AC, Shields GE. A systematic review and network meta-analysis to assess the relative efficacy of antipsychotics for the treatment of positive and negative symptoms in early-onset schizophrenia. CNS Drugs. 2016;30:27–39.
   PubMed Web of Science ®Google Scholar
• Leucht S, Leucht C, Huhn M, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. 2017;174:927–942.
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276.
   PubMed Web of Science ®Google Scholar
• Marques TR, Levine SZ, Reichenberg A, et al. How antipsychotics impact the different dimensions of Schizophrenia: a test of competing hypotheses. Eur Neuropsychopharmacol. 2014;24:1279–1288.
   PubMed Web of Science ®Google Scholar
• Agid O, Kapur S, Arenovich T, et al. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatr. 2003;60:1228–1235.
   PubMed Web of Science ®Google Scholar
• McMahon RP, Kelly DL, Boggs DL, et al. Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research. Schizophr Bull. 2008;34:292–301.
   PubMed Web of Science ®Google Scholar
• Gunduz-Bruce H, McMeniman M, Robinson DG, et al. Duration of untreated psychosis and time to treatment response for delusions and hallucinations. Am J Psychiatry. 2005;162:1966–1969.
   PubMed Web of Science ®Google Scholar
• Schneider SD, Jelinek L, Lincoln TM, et al. What happened to the voices? A fine-grained analysis of how hallucinations and delusions change under psychiatric treatment. Psychiatry Res. 2011;188:13–17.
   PubMed Web of Science ®Google Scholar
• So SH, Peters ER, Kapur S, et al. Changes in delusional dimensions and emotions over eight weeks of antipsychotic treatment in acute patients. Psychiatry Res. 2015;228:393–398.
   PubMed Web of Science ®Google Scholar
• Mizrahi R, Kiang M, Mamo DC, et al. The selective effect of antipsychotics on the different dimensions of the experience of psychosis in schizophrenia spectrum disorders. Schizophr Res. 2006;88:111–118.
   PubMed Web of Science ®Google Scholar
• Evensen J, Røssberg JI, Haahr U, et al. Contrasting monosymptomatic patients with hallucinations and delusions in first-episode psychosis patients: a five-year longitudinal follow-up study. Psychopathology. 2011;44:90–97.
   Google Scholar
• Zhu Y, Li C, Huhn M, et al. How well do patients with a first episode of schizophrenia respond to antipsychotics: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2017;27:835–844.
   PubMed Web of Science ®Google Scholar
• Johnsen E, Kroken RA, Wentzel-Larsen T, et al. Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. BMC Psychiatr. 2010;10:26.
   Google Scholar
• World Health Organization. 2007. International statistical classification of diseases and related health problems, 10th revision. Available from: http://apps.who.int/classifications/icd10/browse/2010/en
   Google Scholar
• Kay SR, Opler LA, Lindenmayer J-P. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatr Res. 1988;23:99–110.
   PubMed Web of Science ®Google Scholar
• Opler L, Kay S, LindenmayerJ, et al. Structured clinical interview: the positive and negative syndrome scale (SCI-PANSS). North Tonawanda (NY): Multi-Health Systems; 1999
   Google Scholar
• Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatr. 1993;163:39–44.
   Web of Science ®Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology. Rockville (MD): US Department of Health, and Welfare; 1976. p. 534–537.
   Google Scholar
• Karterud SPG, Loevdahl H, Friis S. Global assessment of functioning – split version (S-GAF): background and scoring manual. Oslo: Ullevaal University Hospital, Department of Psychiatry; 1998.
   Google Scholar
• WHO. 2018. Definitions and general considerations. Available from: https://www.whocc.no/ddd/definition_and_general_considera/
   Google Scholar
• IBM Corp. 2017. IBM SPSS statistics for Windows. Version 24.0. Armonk (NY): IBM.
   Google Scholar
• Muthén LK, Muthén BO. Mplus 8. Los Angeles (CA): Muthén & Muthén; 2017.
   Google Scholar
• Kline RB. 2010. Principles and practice of structural equation modeling. 3rd ed. New York (NY): The Guilford Press.
   Google Scholar
• Bollen KA, Curran PJ. 2006. Latent curve models: a structural equation perspective. Hoboken (NJ): Wiley-Interscience.
   Google Scholar
• Wang J, Wang X. 2012. Structural equation modeling: applications using Mplus. West Sussex: John Wiley & Sons.
   Google Scholar
• Cramer AO, Waldorp LJ, van der Maas HL, et al. Comorbidity: a network perspective. Behav Brain Sci. 2010;33:137–150; discussion 150-193.
   PubMed Web of Science ®Google Scholar
• Maher BA. Delusional thinking and perceptual disorder. J Individ Psychol. 1974;30:98–113.
   PubMed Web of Science ®Google Scholar
• Maher BA. The relationship between delusions and hallucinations. Curr Psychiatry Rep. 2006;8:179–183.
   PubMedGoogle Scholar
• McCutcheon RA, Abi-Dargham A, Howes OD. Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends Neurosci. 2019;42:205–220.
   PubMed Web of Science ®Google Scholar
• McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatr. 2020;19:15–33.
   PubMed Web of Science ®Google Scholar
• Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III–the final common pathway. Schizophr Bull. 2009;35:549–562.
   PubMed Web of Science ®Google Scholar
• Samara MT, Klupp E, Helfer B, et al. Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia. Cochrane Database Syst Rev. 2018;5:CD011884.
   PubMedGoogle Scholar
• Smith RC, Leucht S, Davis JM. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis. Psychopharmacology (Berl). 2019;236:545–559.
   PubMed Web of Science ®Google Scholar
• Opler MGA, Yavorsky C, Daniel DG. Positive and Negative Syndrome Scale (PANSS) Training: challenges, solutions, and future directions. Innov Clin Neurosci. 2017;14:77–81.
   PubMedGoogle Scholar
• Kahn RS, Winter van Rossum I, Leucht S, et al. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatr. 2018;5:797–807.
   PubMed Web of Science ®Google Scholar
• Haddock G, McCarron J, Tarrier N, et al. Scales to measure dimensions of hallucinations and delusions: the psychotic symptom rating scales (PSYRATS). Psychol Med. 1999;29:879–889.
   PubMed Web of Science ®Google Scholar
• Ostergaard SD, Lemming OM, Mors O, et al. PANSS-6: a brief rating scale for the measurement of severity in schizophrenia. Acta Psychiatr Scand. 2016;133:436–444.
   PubMed Web of Science ®Google Scholar
• Østergaard SD, Opler MGA, Correll CU. Bridging the measurement gap between research and clinical care in schizophrenia: Positive and Negative Syndrome Scale-6 (PANSS-6) and other assessments based on the Simplified Negative and Positive Symptoms Interview (SNAPSI). Innov Clin Neurosci. 2017;14:68–72.
   PubMedGoogle Scholar
• Kølbaek P, Blicher AB, Buus CW, et al. Inter-rater reliability of ratings on the six-item Positive and Negative Syndrome Scale (PANSS-6) obtained using the Simplified Negative and Positive Symptoms Interview (SNAPSI). Nord J Psychiatr. 2018;72:431–436.
   PubMed Web of Science ®Google Scholar
• Alisauskiene R, Løberg E-M, Gjestad R, et al. The influence of substance use on the effectiveness of antipsychotic medication: a prospective, pragmatic study. Nord J Psychiatr. 2019;73:281–287.
   PubMed Web of Science ®Google Scholar
• Leucht S, Heres S, Hamann J, et al. Methodological issues in current antipsychotic drug trials. Schizophr Bull. 2007;34:275–285.
   Web of Science ®Google Scholar